SkyePharma Announces Positive Results for Two European Studies for Flutiform

SkyePharma Posted on:23 Jul 08 LONDON, UK 22 July 2008 - SkyePharma PLC (LSE: SKP) today announces that its development and marketing partner Mundipharma has successfully completed two Phase III clinical studies for the European development programme for Flutiform™, both of which show positive results. Study FLT-3501 assessed 182 patients, suffering from mild to moderate-severe persistent and reversible asthma, who were treated in accordance with the protocol. This randomised, open label, parallel group study compared Flutiform™ pMDI (100 mcg fluticasone & 10mcg formoterol bid, or 250/10 mcg bid, respectively) to Seretide® pMDI (100 mcg fluticasone & 50 mcg salmeterol bid, or 250/50 mcg bid, respectively), with the goal to demonstrate comparable efficacy between treatment arms. Enrolled patients had to have a disease history... [read full story]